Abstract:Limited success has been achieved in ferroptosis-induced cancer treatment due to the challenges related to low production of toxic reactive oxygen species (ROS) and inherent ROS resistance in cancer cells. To address this issue, a self-assembled nanodrug have been investigated that enhances ferroptosis therapy by increasing ROS production and reducing ROS inhibition. The nanodrug is constructed by allowing doxorubicin (DOX) to interact with Fe 2+ through coordination interactions, forming a stable DOX-Fe 2+ chelate, and this chelate further interacts with sorafenib (SRF), resulting in a stable and uniform nanoparticle. In tumor cells, overexpressed glutathione (GSH) triggers the disassembly of nanodrug, thereby activating the drug release. Interestingly, the released DOX not only activates nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) to produce abundant H 2 O 2 production for enhanced ROS production, but also acts as a chemotherapeutics agent, synergizing with ferroptosis. To enhance tumor selectivity and improve the blood clearance, the nanodrug is coated with a related cancer cell membrane, which enhances the selective inhibition of tumor growth and metastasis in a B16F10 mice model. Our findings provide valuable insights into the rational design of self-assembled nanodrug for enhanced ferroptosis therapy in cancer treatment. Statement of significance Ferroptosis is a non-apoptotic form of cell death induced by the iron-regulated lipid peroxides (LPOs), offering a promising potential for effective and safe anti-cancer treatment. However, two significant challenges hinder its clinical application: 1) The easily oxidized nature of Fe2+ and the low concentration of H 2 O 2 leads to a low efficiency of intracellular Fenton reaction, resulting in poor therapeutic efficacy; 2) The instinctive ROS resistance of cancer cells induce drug resistance. Therefore, we developed a simple and high-efficiency nanodrug composed of self-assembling by Fe 2+ sources, H 2 O 2 inducer and ROS resistance inhibitors. This nanodrug can effectively deliver the Fe 2+ sources into tumor tissue, enhance intracellular concentration of H2O2, and reduce ROS resistance, achieving a high-efficiency, precise and safe ferroptosis therapy.

Synergistic anticancer therapy via ferroptosis using modified bovine serum albumin nanoparticles loaded with sorafenib and simvastatin

Enhancing anti-cancer potential by delivering synergistic drug combinations via phenylboronic acid modified PLGA nanoparticles through ferroptosis-based therapy

Cancer-Erythrocyte Membrane-Mimicking Fe3O4 Nanoparticles and DHJS for Ferroptosis/Immunotherapy Synergism in Tumors.

Multimodal synergistic ferroptosis cancer therapy

Zwitterionic Polymer Coated Sorafenib-Loaded Fe3O4 Composite Nanoparticles Induced Ferroptosis for Cancer Therapy.

Vitamin B2‐Based Ferroptosis Promoter for Sono‐Enhanced Nanocatalytic Therapy of Triple‐Negative Breast Cancer

A homologous membrane-camouflaged self-assembled nanodrug for synergistic antitumor therapy

Simvastatin Induced Ferroptosis for Triple-Negative Breast Cancer Therapy

Sorafenib Sensitization in Tumor Therapy by Iron Overload and AMPK Activation

A Biomimetic Nanodrug Self-Assembled from Small Molecules for Enhanced Ferroptosis Therapy

Bio-inspired Engineered Ferritin-Albumin Nanocomplexes for Targeted Ferroptosis Therapy.

Exploiting Cancer Vulnerabilities by Blocking of the DHODH and GPX4 Pathways: A Multifunctional Bodipy/PROTAC Nanoplatform for the Efficient Synergistic Ferroptosis Therapy

Tumor‐targeted and microenvironment‐activatable iron‐based nMOF for synergistic inducing ferroptosis

Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy

Co‐Delivery of siNRF2 and Sorafenib by a “Click” Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma

Spatially Asymmetric Nanoparticles for Boosting Ferroptosis in Tumor Therapy.

Ferrous-Supply-Regeneration Nanoengineering for Cancer-Cell-Specific Ferroptosis in Combination with Imaging-Guided Photodynamic Therapy.

Ferroptosis boosted oral cancer photodynamic therapy by carrier-free Sorafenib-Ce6 self-assembly nanoparticles

Hypoxia-responsive nanoreactors based on self-enhanced photodynamic sensitization and triggered ferroptosis for cancer synergistic therapy

Supramolecularly Engineered Conjugate of Bacteria and Cell Membrane‐Coated Magnetic Nanoparticles for Enhanced Ferroptosis and Immunotherapy of Tumors

Ferroptosis resistance in cancer cells: nanoparticles for combination therapy as a solution